Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Curti

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson, Brendan D Curti, Bruce G Redman, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Alterations in T cell receptor and signal transduction molecules in melanoma patientsA H Zea, B D Curti, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Oncoimmunology|December 8, 2018
Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancerRieneke van de Ven, Traci L Hilton, Hong-Ming Hu, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Cancer Research|December 3, 2015
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with IpilimumabYoshinobu Koguchi, Helena M Hoen, Shelly A Bambina, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson, Brendan D Curti, Bruce G Redman, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Alterations in T cell receptor and signal transduction molecules in melanoma patientsA H Zea, B D Curti, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Oncoimmunology|December 8, 2018
Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancerRieneke van de Ven, Traci L Hilton, Hong-Ming Hu, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Cancer Research|December 3, 2015
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with IpilimumabYoshinobu Koguchi, Helena M Hoen, Shelly A Bambina, et al.
Pageof 13